<DOC>
	<DOC>NCT02882009</DOC>
	<brief_summary>The purpose of this randomized, open-label, parallel-group, placebo-controlled study is to assess pain following subcutaneous (SC) administration of gantenerumab as a high-concentration liquid formulation (HCLF) at different injection speeds. The total duration of the study for each healthy participant will be up to approximately 21 weeks.</brief_summary>
	<brief_title>A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Healthy male and female participants (healthy status is defined by the absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12lead electrocardiogram, hematology, blood chemistry, coagulation, serology, and urinalysis) Body mass index between 18.0 and 30.0 kilograms per meter squared (kg/m^2), inclusive Female participants of childbearing potential must commit to use two acceptable forms of contraception during the study and until at least 6 months after the followup visit History of any clinically significant gastrointestinal, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardiovascular, endocrinological, hematological or allergic disease, metabolic disorder, cancer, or cirrhosis History or suspicion of drugs of abuse or alcohol addiction Smokers who smoke more than 10 cigarettes per day or equivalent amount of tobacco as determined by history Pregnant or lactating women Positive result on hepatitis B virus (HBV), hepatitis C virus (HCV), or Human immunodeficiency virus (HIV)1 and 2 Any familial history of early onset Alzheimer's disease Prior administration of gantenerumab Participation in an investigational drug medicinal product or medical device study within 90 days before dosing or within seven times the elimination halflife, whichever is longer Any abnormal skin conditions or potentially obscuring tattoos, pigmentation, or lesions in the area intended for SC injection</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>